This article explains, in educational terms, intracavitary hypothermia bladder cancer — how the technology works and where it fits. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding.
Intracavitary Hypothermia for Bladder Cancer
Intracavitary hypothermia delivers controlled temperature therapy directly into the bladder, and is generally described as an adjunct intended to enhance the penetration and effect of intravesical chemotherapy rather than as a standalone ablation. By modulating the local temperature of the bladder wall and instilled agent, the approach is designed to support drug delivery to the urothelium in appropriately selected patients. INVAMED's HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment is an intravesical temperature-therapy set positioned for adjunctive use alongside intravesical chemotherapy for bladder cancer. Patient selection, the chemotherapy regimen, and the treatment schedule are determined by the treating oncology and urology team.
Design and Technical Notes
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone. Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
Key Considerations
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
Frequently Asked Questions
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes. Antenna gauge, active-tip length, and generator power (measured in watts) are the primary variables a clinician balances against the intended ablation zone size for a given lesion. INVAMED's ablation focus is centered on its radiofrequency platforms and intracavitary hypothermia set, so modality selection is made by the treating team based on available tools and indications. Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy.
Related on INVAMED
- Oncology Ablation — product category
- What size tumor can be ablated (the 3 cm rule)?
- Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors — Technical Overview
- Cryoablation vs Microwave ablation: What Is the Difference?
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.